The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Clomipramine Hydrochloride Capsules USP in the strengths 25 mg, 50 mg, and 75 mg, Alembic Pharmaceuticals said in a regulatory filing.
Read more about Glenmark Pharma gets approval for Theophylline Tablets on Business Standard. Glenmark Pharmaceuticals on Friday announced that it has received final approval from the USFDA for Theophylline extended release tablets.
Read more about Glenmark receives USFDA approval for Theophylline ER Tablets on Business Standard. Glenmark has been granted a competitive generic therapy (CGT) designation for Theophylline Extended-Release Tablets USP, 450 mg, therefore, with this approval, Glenmark is the first approved applicant for such competitive generic therapy and is
Dish TV India Ltd saw volume of 756.93 lakh shares by 14:14 IST on NSE, a 12.61 fold spurt over two-week average daily volume of 60.02 lakh shares
Grindwell Norton Ltd, Angel Broking Ltd, Venkys (India) Ltd, Alembic Ltd are among the other stocks to see a surge in volumes on NSE today, 04 May 2021.
Dish TV India Ltd saw volume of 756.93 lakh shares by 14:14 IST on NSE, a 12.61 fold spurt over two-week average daily volume of 60.02 lakh shares. The stock increased 13.00% to Rs.11.30. Volumes stood at 123.6 lakh shares in the last session.
Grindwell Norton Ltd notched up volume of 4.78 lakh shares by 14:14 IST on NSE, a 10.07 fold spurt over two-week average daily volume of 47458 shares. The stock rose 8.86% to Rs.1,004.00. Volumes stood at 38742 shares in the last session.
Five under-valued pharma stocks to buy
These are firms with strong financials and relatively reasonable valuations
With the outbreak of the Covid-19 pandemic, investors latched on to stocks from defensive sectors such as pharmaceuticals, IT and FMCG to beat market volatility. Investors in such stocks were handsomely rewarded in 2020. Take for instance, the S&P BSE Healthcare Index that surged 97 per cent from the March low until December-end 2020.
With the economy showing definite signs of revival, also testified by the December quarter company results, cyclicals stocks are set to do well. While the pharmaceutical sector may not offer another successive year of spectacular returns, one can still search good long-term bets here.